IPS HEART, Resident of Johnson & Johnson Innovation, Uses Human Stem Cells for the First Time to Actually Reverse Heart Attack Damage

HOUSTON–(BUSINESS WIRE)–IPS HEART, resident of Johnson & Johnson Innovation, JLABS is pioneering the use of IPS cellular therapy for the replacement of heart tissue after heart attack, heart failure and duchenne cardiomyopathy. Recent results were presented at the 82nd Annual Scientific Meeting of the Japanese Circulation Society showing over 66% ejection fraction (EF) improvement after 90 days in a mouse model of heart attack treated with our human derived IPS HEART cardiomyocytes. These results contrast all previous cardiac stem cell trials, which showed at best 3% EF improvement and no actual heart regeneration. Our remarkable results, which are further substantiated with the completion of Phase I ESCORT trial in Paris, demonstrate the validity of our moonshot approach. With $12 million in research funding thus far, IPS HEART founded in 2014 is the first company to focus exclusively on the IPS cardiac arena and is currently raising venture capital to expand into global clinical trials.

IPS HEART is pleased to announce the addition to its Board, Dr. John Lynn Jefferies, Director Advanced Heart Failure and Cardiomyopathy Programs at the Cincinnati Children’s Hospital Medical Center. Dr. Jefferies has recently completed a Phase I study in Duchenne Cardiomyopathy. He joins other prestigious members including Dr. Philippe Menasche, Professor of Thoracic and Cardiovascular Surgery, University of Paris Descartes. Dr. Menasche is currently the world’s first and only clinician to have a Phase I cardiomyocyte stem cell clinical trial in Paris, which recently announced promising results and provides a proof of concept for work similar to IPS HEART.

About IPS HEART:

IPS HEART is a privately-held biopharmaceutical company dedicated to addressing heart attack, heart failure and duchenne cardiomyopathy via next generation cellular therapy. IPS HEART was the first company to exclusively focus on induced pluripotent stem cells and heart disease. IPS HEART is a resident at Johnson & Johnson Innovation, JLABS at TMC in the Texas Medical Center. For more information, please visit www.ipsheart.com.